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Abstract: Introduction: Endometrial polyps (EP) are common within the gynaecological practice. The aims of this study 
are to evaluate the risk of premalignant and malignant changes in EP and to determine the predictors of histological 
outcomes of these lesions. 
Methods: This is a retrospective study conducted over a 12-year period between January 2000 and 2012. Data were 
retrieved from patients’ and theatre records. The histopathology reports of all cases were retrieved. All cases with 
confirmed EP at hysteroscopy were identified. 
Results: There were a total of 397 cases. Age range was between 24 and 89 years, median age at presentation was 54 
years. Histology outcomes were classified into benign, premalignant (hyperplasia with atypia) and malignant. Age 
greater 60 years was strongly associated with abnormal histology i.e. premalignant and malignant changes in polyps 
(OR 2.174 [CI 1.645-2.874], p<0.001) Menopausal status showed a strong link with abnormal histology (OR 1.599 [CI 
1.388- 1.842], p<0.001). These patients were about one and a half times more likely to have abnormal histology in the 
event of a polyp. The results are similar with premalignant histology (OR 1.610 [CI 1.394- 1.860], p<0.001). 
Results for patients presenting with postmenopausal bleeding were also positive. They were more likely to have 
abnormal histology compared to patients with other symptoms (OR1.776 [CI 1.516-2.079], p<0.001). Postmenopausal 
bleeding is also strongly associated with premalignancy (OR 1.782 [CI 1.515- 2.096], p<0.001). The use of hormone 
replacement therapy (HRT) or tamoxifen was not associated with abnormal histology (p= 0.114 and p=0.668 
respectively) or premalignancy (p= 0.138 and p= 0.764 respectively). 
Polyps greater than 15mm were not associated with abnormal histology (OR 1.313 [CI 0.932-1.850], p= 0.143) or 
premalignancy (OR 1.292 [CI 0.896-1.864], p= 0.196). 
Conclusion: There is a strong link between patients’ age and menopausal status with abnormal or premalignant 
histology. Postmenopausal bleeding is also an important predictor of abnormal or premalignant changes at histology. 
	: Endometrial polyp, Abnormal histology, Premalignancy, Tamoxifen, Hormone replacement therapy, 
Postmenopausal.
INTRODUCTION 
Endometrial polyp (EP) is a common presentation 
within the gynaecological practice. It is the most 
frequent endometrial finding in menopausal women [1]. 
It is usually benign [2]
 
but may be associated with 
malignancy [3]. Women commonly present with 
abnormal uterine bleeding but a few are asymptomatic, 
discovered at routine ultrasound investigations for other 
reasons including infertility [2, 4-5]. Its prevalence is 
7.8% within the population, increasing with age [6]. 
They are diagnosed in 5.8% of pre and 11.8% of 
postmenopausal women [6]. Lieng et al. [7] in their 
systematic review described a pooled prevalence of 
0.8% and 3.1% of premalignant and malignant tissue 
changes respectively within polyps. The prevalence of 
malignancy varies significantly with age and 
menopausal status [7-12], with the postmenopausal 
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group of patients presenting with abnormal uterine 
bleed having the highest risk of premalignant and 
malignant tissue changes [7-8,13]. Lee et al. [14] in 
their meta-analysis reported a prevalence of 5.42% and 
1.7% for premalignant and malignant polyps 
respectively for postmenopausal women in general 
[14]. There are conflicting reports on the sizes of polyps 
that might be relevant as a predictor of malignancy. 
Some studies have shown sizes of greater than 15mm 
[11] and 18mm as significant factors for premalignant 
and malignant changes [15]. Endometrial polyps 
represent the most common endometrial pathology 
associated with postmenopausal tamoxifen use [16]. 
The use of tamoxifen predisposes patient to the 
development of EPs [16-17] and polyps tend to be 
larger for those taking tamoxifen compared to those 
that are not [18]. Kennedy and colleagues described 
the histological features as characteristically multiple 
and fibrotic, with a high rate showing malignant change 
[17].
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he aims of this study are to evaluate the risk of 
premalignant and malignant changes in EPs and to 
determine predicators of histological outcomes of these 
lesions.  
MATERIALS AND METHODS 
This is a retrospective study conducted over a 12-
year period between 2000 and 2012 at Singleton 
hospital, a major district hospital in South Wales, 
United Kingdom. Data were retrieved from patients’ 
and theatre records. The histopathology reports in all 
cases were retrieved. All cases with confirmed EP at 
hysteroscopy were identified. These include all pre and 
postmenopausal women who had endometrial polyps 
confirmed at hysteroscopy within the study period. Data 
analysed include the age, polyp size, and menopausal 
status. Data were also retrieved on use of hormone 
replacement therapy (HRT), current use of tamoxifen 
and histology results. Women were considered 
menopausal if they reported amenorrhea of at least 12 
months after the age of 45 years.  Abnormal uterine 
bleeding was defined as vaginal bleeding in post- 
menopausal women not receiving HRT or as irregular 
vaginal bleeding in women still actively menstruating or 
being treated with HRT. Histology results were 
classified as benign, pre-malignant, and malignant. 
Cases with simple and complex hyperplasia without 
atypia were classified as benign. ‘Pre-malignant’ refers 
to hyperplastic endometrium with atypia while 
‘malignant’ were patients diagnosed with endometrial 
cancer In the analysis, abnormal histology refers to 
number of cases with malignant changes plus number 
of polyps with premalignant changes at histological 
examination. Results are presented as mean+/- S.D. 
Data were analysed using IBM SPSS Statistics 20 to 
determine Chi square and risk ratio. The level of statistical 
significance at which the null hypothesis was rejected was 
chosen at 0.05.  
RESULTS  
There were 397 cases of polyps confirmed at 
hysteroscopy. The age range was between 24 and 89 
years with a median age of 54 years. 56% of patients 
were postmenopausal; and 88% of all the cases were 
done as day case procedures. 12 patients had been on 
tamoxifen at the time of presentation, while 17 patients 
were on HRT. The Table 1 below describes the 
symptoms patients presented with and the histological 
outcomes. 
Postmenopausal bleeding accounted for about 53% 
of the cases. 8 patients had endometrial polyps 
confirmed at hysteroscopy as part of their investiga- 
tions for infertility. There was one patient with EP 
confirmed at hysteroscopy for recurrent vaginal 
discharge. 
Patients’ symptoms at presentation varied 
particularly with age; patients presenting with 
postmenopausal bleeding were 53% of the entire 
cohort and dysfunctional uterine bleeding made up 
37% of the cases. The prevalence of malignant EP in 
premenopausal women was 0.6%, increasing to 2.1% in 
postmenopausal women. 
Age greater than 60 years had a very significant 
association with abnormal histology i.e. premalignant 
and malignant changes in polyps (OR 2.174 [CI 1.645- 
2.874.], p<0.001). Patients older than 60 years of age 
were twice as likely to have polyp with atypical hyper- 
plasia compared to women below 60 years i.e. premalig- 
nant changes (OR 2.147 [CI 1.600- 2.882], p<0.001).  
Menopausal status showed a strong link with 
abnormal histology (OR 1.599 [CI 1.388- 1.842], 
p<0.001). Postmenopausal women were about one 
and a half times more likely to have abnormal histology 
of endometrial polyp compared with premenopausal 
women. The results were similar for premalignant 
histology (OR 1.610 [CI 1.394- 1.860], p<0.001).  
Results for patients presenting with postmeno- 
pausal bleeding were also significant. Patients 
presenting with postmenopausal bleeding were more 
likely to have abnormal histology compared to patients 
with other symptoms (OR 1.776 [CI- 1.516- 2.079], 
p=0.001). Postmenopausal bleeding is also strongly 
associated with premalignancy (OR 1.782 [CI- 1.515- 
2.096], p<0.001).  
There were 33 patients who were asymptomatic. 
They had polyps’ diagnosed following radiological 
assessment for other symptoms. EP diagnosed in 
patients without symptoms are not associated with 
abnormal histology (OR 0.458 [CI 0.113- 1.855], 
p=0.252) or with premalignancy (OR 0.522 [CI 0.129- 
2.105], p= 0.343). 30 out of the 33 asymptomatic 
patients were postmenopausal. The probability that an 
asymptomatic menopausal patient with EP will have an 
abnormal or premalignant histology is negligible (OR 
0.507 [CI 0.125- 2.063], p=0.326; OR 0.578, [CI 0.143- 
2.342], p=0.430) respectively). 
The use of HRT was not a predictor of abnormality. 
There was no association with abnormal histology or 
premalignancy (p=0.114 and p= 0.138 respectively). 
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Tamoxifen use was not associated with either 
abnormal histology (OR 0.646 [CI 0.085- 4.892], 
p=0.668) or premalignancy (OR 0.736 [CI 0.097- 
5.560], p= 0.764). 
Polyps were also classified into two groups of 
<15mm and >15mm. Polyps greater than 15mm were 
unlikely to be associated with abnormal histology 
(OR 1.313 [CI- 0.932- 1.850], p= 0.143) or 
premalignancy (OR 1.292 [CI- 0.896- 1.864], p= 0.196). 
Polyps were further grouped into intervals of 10mm 
(Tables 2 and 3). Data were analysed to determine if 
there was an association with increasing sizes of the 
polyp and abnormal histology/premalignancy. There 
was no association between increasing polyp size and 
abnormal histology see (Table 2) or premalignancy 
(Table 3). 
Table 2: This Table Illustrates the Association between 
Increasing Polyps’ Size and Abnormal 
Histology 
Polyp Size p-Value Rate Ratio (RR) 
Confidence 
Interval (CI) 
 10mm Reference   
11-20mm 0.614 0.956 0.804-1.138 
21-30mm 0.784 0.971 0.785-1.201 
31-40mm 0.986 0.997 0.714-1.393 
41-50mm 0.842 1.049 0.654-1.685 
 50mm 0.990 0.997 0.629-1.581 
DISCUSSION  
EP remains a common presentation in gynaecol- 
ogical practice. There is variation in the management of 
EP especially when they are incidental findings while 
investigating for other conditions. This is a study of 
women with EP over a period of 12 years. 
Approximately 12% of diagnosed cases had 
premalignant and malignant changes confined to 
polyps. About 11% of cases had hyperplasia with 
atypia while 1.5% of patients had carcinoma confined 
to EP. Our study analysed size of polyp in two ways: (i) 
absolute sizes i.e. <15mm or >15mm and (ii) at 
intervals of 10mm. There is no previous study in the 
literature that has analysed the size of EP in this way. 
There was no association with abnormal histology or 
premalignancy in either sub-group.  
 
Table 3: This Table Illustrates the Association between 
Increasing Polyps’ Size and Premalignancy 
Polyp Size p-Value Rate Ratio (RR) 
Confidence 
Interval (CI) 
 10mm Reference   
11-20mm 0.739 0.971 0.815-1.156 
21-30mm 0.822 0.976 0.788-1.208 
31-40mm 0.974 0.994 0.712-1.389 
41-50mm 0.850 1.047 0.652-1.680 
 50mm 0.981 0.994 0.627-1.577 
 
Age was a significant predictor of abnormal 
histology. Older women have a higher chance of 
abnormal histology. 25% of patients over the age of 60 
years were diagnosed with premalignant and malignant 
changes at histology. Patients over 60 years were 
twice as likely to have abnormal or premalignant 
changes at histology compared with patients below 60 
years. This is similar to many previous studies [7-9,11]. 
Antunes and colleagues claimed that postmenopausal 
women over 60 years were 5 times more likely to have 
premalignant and malignant changes in EP [9].  
Table 1:  
Histology  
Benign Pre-Malignant Malignant 
Total 
Asymptomatic 31 2 0 33 
Post menopausal bleeding 168 37 5 210 
Dysfunctional uterine bleeding 140 4 1 145 
As part of investigations for infertility 8 0 0 8 
Symptoms 
Recurrent vaginal discharge 1 0 0 1 
Total 348 43 6 397 
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Menopausal status is a strong predictor of abnormal 
histology. In their meta-analysis, Lee and associates 
identified this as predictor for malignancy [14]. Our 
study showed that postmenopausal women were 
almost twice as likely to have premalignant/malignant 
polyp as premenopausal women. Our study also 
showed that increasing age is a predictor of abnormal 
histology, which is similar to findings by previous 
studies in the literature [7-9,11]. 
Postmenopausal bleeding is also a relevant 
predictor, with women presenting with the symptom 
twice as likely to have premalignant or malignant 
changes at histology compared to women with other 
symptoms 
Table 4: This Table is a Summary of Relevant Results 
from the Study (See Below) 
 
p-Values 
Odd’s 
Ratio  
Confidence 
Interval 
Age >60 years <0.001 2.174 1.645- 2.874 
Menopausal status <0.001  1.599 1.388- 1.842 
Post menopausal bleeding 0.001 1.776 1.516- 
2.079) 
Hormone replacement therapy, 
Tamoxifen, Polyp size 
NS   
NS - not significant. 
There was no association between tamoxifen or use 
of hormone replacement therapy (HRT) and 
premalignant or malignant changes in polyps. These 
findings differ from that other of other studies [19-20]. 
This discrepancy may be due to the relatively small 
numbers of patients on tamoxifen and HRT in our 
study.  
Patients that are asymptomatic are unlikely to have 
premalignant or malignant changes of EP. The 
diameter of the polyp was not significant in the 
prediction of abnormal histology. Ferrazzi and 
colleagues, in their series, revealed that polyps greater 
than 18mm were likely to be associated with abnormal 
histology [15]. The difference in findings might be due 
to relatively small number of asymptomatic cases in our 
study compared to their study.  
In conclusion, patients over the age of 60 years, 
menopausal status and postmenopausal bleeding are 
predictors of abnormal histology in endometrial polyps. 
This is the first study in the literature to evaluate 
increasing polyp size relative to abnormal histology and 
premalignancy. Our study shows that there is no 
association between these parameters. Patients and 
clinicians should be aware of these findings when 
making decisions on the clinical management of EP. 
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